Is Sunitinib included in medical insurance?

Sunitinib (Sunitinib) is approved to treat gastrointestinal stromal tumors (a type of gastric cancer) in adults in patients whose disease has worsened while taking imatinib mesylate or in patients who are unable to take it. Sunitinib is also used in patients with progressive neuroendocrine tumors (pancreatic cancer) that cannot be removed by surgery or have spread. Sunitinib is also used as adjuvant therapy to treat advanced renal cell carcinoma (a type of kidney cancer) in cancer patients who have undergone nephrectomy (surgery to remove the kidney) and have a high risk of cancer recurrence. Sunitinib is also being studied to treat other types of cancer.

Maximum plasma concentrations of sunitinib (Cmax) are typically observed between 6 and 12 hours after oral administration (Tmax). Food has no effect on the bioavailability of sunitinib. Sunitinib can be taken with or without food. Pharmacokinetics are similar in healthy volunteers and patients with solid tumors, including patients with GIST and RCC.

The original sunitinib drug has been launched in China and has entered the scope of Class B medical insurance. SpecificationsThe price of 12.5mg*28 tablets is around RMB 3,500. The reimbursement ratio is different in different regions, and the price after reimbursement is different. The original sunitinib drug has also been launched overseas. The price of 12.5mg*7 tablets is around RMB 1,500 (the price may fluctuate due to the exchange rate). There are also generic drugs produced in other countries. The price of 12.5mg*28 tablets produced by Du Pharmaceutical Factory is around RMB 750 (the price may fluctuate due to the exchange rate). The generic drugs produced abroad are basically the same as the domestic and foreign original drugs. The prices of drugs of different specifications may be different.